Radioligand therapy significantly prolongs progression-free survival in metastatic GEP-NETs

Medical Xpress

Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared with targeted therapy with everolimus. ...

전문 보기

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

Radioligand therapy significantly prolongs progression-free survival in metastatic GEP-NETs

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

STAT+: ‘Secret shopper’ study probes GLP-1 telehealth sites

Watching how molecules change shape in slow motion could inform future molecular machines

A new soccer concussion protocol could make one of the game's hardest calls much faster

Medical Xpress의 다른 기사

New approach could expand CAR T therapy from blood cancers to solid tumors

Could these tiny organs save millions of lives?

Using AI to provide new insights into why Ebola outcomes differ between patients